Splenic Volume as a Surrogate Marker of Immune Checkpoint Inhibitor Efficacy in Metastatic Non Small Cell Lung Cancer

SIMPLE SUMMARY: Monoclonal antibodies targeting PD1/PD-L1 are game changers in the treatment of advanced non-small cell lung cancer (NSCLC), but biomarkers are lacking. We previously reported the prognostic role of splenic volume in digestive cancer and its correlation with the presence of immunosup...

Descripción completa

Detalles Bibliográficos
Autores principales: Galland, Loïck, Lecuelle, Julie, Favier, Laure, Fraisse, Cléa, Lagrange, Aurélie, Kaderbhai, Courèche, Truntzer, Caroline, Ghiringhelli, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8234633/
https://www.ncbi.nlm.nih.gov/pubmed/34208673
http://dx.doi.org/10.3390/cancers13123020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8234633/
https://www.ncbi.nlm.nih.gov/pubmed/34208673
http://dx.doi.org/10.3390/cancers13123020

Ejemplares similares